Insider Selling: Johnson & Johnson (NYSE:JNJ) EVP Sells 13,072 Shares of Stock

Key Points

• Johnson & Johnson EVP Elizabeth Forminard sold 13,072 shares for about $3.72 million, reducing her direct stake by 43.48% to 16,994 shares.
• J&J’s latest quarter slightly beat expectations, reporting adjusted EPS of $2.59 and revenue of $25.40 billion; revenue rose 5.9% year over year.
• The company announced a quarterly dividend of $1.34 per share, equivalent to $5.36 annually and a 1.9% yield.

Johnson & Johnson (NYSE:JNJ - Get Free Report) EVP Elizabeth Forminard sold 13,072 shares of the company's stock in a transaction that occurred on Thursday, November 12th. The stock was sold at an average price of $284.39, for a total transaction of $3,717,546.08. Following the sale, the executive vice president directly owned 16,994 shares in the company, valued at $4,832,923.66. This trade represents a 43.48% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Johnson & Johnson Price Performance

NYSE JNJ traded up $2.26 on Friday, hitting $285.78. The stock had a trading volume of 6,276,993 shares, compared to its average volume of 7,952,034. The firm has a 50-day moving average of $266.83 and a 200-day moving average of $249.54. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.74 and a current ratio of 1.02. Johnson & Johnson has a 52-week low of $193.55 and a 52-week high of $288.11. The company has a market capitalization of $687.95 billion, a price-to-earnings ratio of 43.30, a price-to-earnings-growth ratio of 2.77 and a beta of 0.22.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, beating analysts' consensus estimates of $2.53 by $0.06. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The firm had revenue of $25.40 billion during the quarter, compared to analyst estimates of $25.38 billion. During the same period in the previous year, the business earned $2.80 EPS. The business's revenue for the quarter was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Equities analysts expect that Johnson & Johnson will post 11.12 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be paid a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a yield of 1.9%. The ex-dividend date is Tuesday, November 24th. Johnson & Johnson's dividend payout ratio is currently 81.21%.

Key Stories Impacting Johnson & Johnson

Here are a few of the latest stories about JNJ:

• Positive Sentiment: A Johnson & Johnson prostate-cancer drug combination is advancing into Phase 3, a meaningful clinical milestone that could strengthen the company’s oncology pipeline, although trial and commercial outcomes remain uncertain. Johnson & Johnson stock advances as prostate drug combo enters Phase 3
• Positive Sentiment: J&J is backing Francis Medical as it advances a water-vapor prostate-cancer treatment device toward FDA premarket approval. The investment expands its reach in minimally invasive oncology treatment. J&J leads Francis Medical investment to fund prostate cancer device
• Positive Sentiment: JNJ has risen 10.4% since its latest earnings report, and State Street’s Health Care SPDR added shares on Nov. 10. These reports suggest continued investor interest, though neither guarantees further gains. Johnson & Johnson Up 10.4% Since Last Earnings Report State Street Health Care SPDR Adds Johnson & Johnson

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. Evercore set a $300.00 price target on Johnson & Johnson in a research report on Tuesday, October 20th. Argus set a $300.00 price objective on Johnson & Johnson in a report on Wednesday, July 29th. Royal Bank Of Canada decreased their price objective on shares of Johnson & Johnson from $290.00 to $280.00 and set an "outperform" rating on the stock in a research report on Wednesday, October 14th. JPMorgan Chase & Co. raised their target price on shares of Johnson & Johnson from $270.00 to $285.00 and gave the company a "neutral" rating in a research note on Tuesday, September 29th. Finally, Raymond James Financial set a $280.00 target price on shares of Johnson & Johnson in a research report on Monday, August 3rd. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $275.92.

Institutional Investors Weigh In On Johnson & Johnson

A number of large investors have recently added to or reduced their stakes in JNJ. CKW Financial Group grew its stake in shares of Johnson & Johnson by 0.9% in the 3rd quarter. CKW Financial Group now owns 4,269 shares of the company's stock valued at $1,104,000 after buying an additional 37 shares in the last quarter. Silver Coast Investments LLC increased its holdings in Johnson & Johnson by 3.8% in the second quarter. Silver Coast Investments LLC now owns 1,066 shares of the company's stock worth $271,000 after buying an additional 39 shares during the last quarter. Townsend Asset Management Corp NC ADV raised its position in Johnson & Johnson by 0.6% during the second quarter. Townsend Asset Management Corp NC ADV now owns 6,418 shares of the company's stock valued at $1,630,000 after acquiring an additional 39 shares in the last quarter. Triumph Capital Management raised its position in Johnson & Johnson by 1.6% during the second quarter. Triumph Capital Management now owns 2,531 shares of the company's stock valued at $643,000 after acquiring an additional 39 shares in the last quarter. Finally, Kwmg LLC lifted its stake in Johnson & Johnson by 1.7% in the third quarter. Kwmg LLC now owns 2,383 shares of the company's stock valued at $631,000 after acquiring an additional 39 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.